• Return to Headlines

Relatively Good Performance Detected in Shares of Clovis Oncology in the Biotechnology Industry (CLVS , AMAG , ESPR , ALKS , AIMT )

By Nick Russo

We looked at the Biotechnology industry and measured relative performance to find the top stocks. Relative outperformance is a bullish sign of underlying fundamental and technical strength. We look at yesterday's price action of all companies in this peer group.

Clovis Oncology (NASDAQ:CLVS ) ranks first with a gain of 11.60%; Amag Pharmaceuti (NASDAQ:AMAG ) ranks second with a gain of 6.90%; and Esperion Therape (NASDAQ:ESPR ) ranks third with a gain of 5.25%.

Alkermes Plc (NASDAQ:ALKS ) follows with a gain of 4.63% and Aimmune Therapeu (NASDAQ:AIMT ) rounds out the top five with a gain of 3.89%.

SmarTrend is tracking the current trend status for Clovis Oncology and will alert subscribers who have CLVS in their portfolio or watchlist when shares have changed trend direction.

Keywords: relative performance clovis oncology amag pharmaceuti esperion therape alkermes plc aimmune therapeu

Ticker(s): CLVS AMAG ESPR ALKS AIMT